Key result
Metabolic syndrome is linked to significantly elevated levels of specific circulating microRNAs versus healthy controls.
Why the study?
The expression pattern of circulating microRNAs in metabolic syndrome Egyptian male patients was not well characterized.
Do circulating microRNAs (miR-486-5p, miR-497, miR-509-5p, and miR-605) differ between Egyptian male patients with metabolic syndrome and healthy controls?
Case-Control (n=75)
Do circulating microRNAs (miR-486-5p, miR-497, miR-509-5p, and miR-605) differ between Egyptian male patients with metabolic syndrome and healthy controls?
Circulating miR-486-5p, miR-497, miR-509-5p, and miR-605 are elevated in men with metabolic syndrome and may serve as potential biomarkers for the condition.
Objective: This study aims to evaluate the expression pattern of circulating microRNAs (miR)-486-5p, miR-497, miR-509-5p, and miR-605 in the serum of metabolic syndrome (MetS) Egyptian male patients. Methods: In this study, the circulating miR-486-5p, miR-497, miR509-5p, and miR-605 were amplified and quantitatively detected by quantitative real-time polymerase chain reaction in sera of 55 MetS male patients in comparison to 20 male controls. The level of fasting plasma glucose and triacylglycerol (TAG) were measured using calorimetric assay. Blood pressure was measured using mercuric sphygmomanometer. Anthropometric measurements were done to each individual. Furthermore, MetS patients were defined according to the criteria proposed by the American Heart Association and divided into three groups according to MetS index. Results: The study was performed on three groups and a control group defined as follows: group 1: 15 MetS patients who fulfilled all diagnostic criteria of MetS; group 2: 20 MetS patients with normal blood pressure; group 3: 20 MetS patients with normal TAG levels.The levels of miRs are expressed as [median (IQR)]. miR-486-5-p and miR-497 expression were elevated in group 1 [31.9(49), p˂ 0.0001; 73.1(42.5), p˂ 0.0001], group 2 [36.4(15.7), p˂ 0.0001; 68.3(54.8), p˂ 0.0001], and group (3) [10.8(18.9), p= 0.0014; 27.5(39.7), p= 0.0012]. MiR-509-5p was elevated in groups 1 and 2 [501(468), p= 0.0001], [309(436), p= 0.0006], respectively, while normally expressed in group 3 [0.93(0.077), p= 0.0001]. miR-605 was elevated in groups 1 and 3 [25.4(20.0), p= 0.0018], [54.8(65.8), p˂ 0.0001], while normally expressed in group 2 [0.84(0.67), p˂ 0.0001]. Conclusion: miRs (486-5p, 497, 509-5p, and 605) serum levels were higher in MetS patients than in healthy control subjects; therefore, these serum miRs can serve as early biomarkers and can be used to follow-up the prognosis of MetS.
No takes yet. Share an insight, caveat, or question.
Zaki et al. (2019) conducted a case-control in Metabolic syndrome (n=75). Metabolic syndrome vs. Healthy controls was evaluated on Expression levels of circulating miR-486-5p, miR-497, miR-509-5p, and miR-605. Metabolic syndrome in Egyptian male patients was associated with significantly elevated serum levels of circulating microRNAs (486-5p, 497, 509-5p, and 605) compared to healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: